Finance
S&P 500 7,757.17 +44.60 +0.58% Dow 52,856.10 +360.20 +0.69% Nasdaq 26,702.86 +278.04 +1.05% NYSE Composite 24,253.12 +62.52 +0.26% Russell 2000 2,781.02 +7.60 +0.27% VIX 18.23 +1.55 +9.29%

MBIO · Mustang Bio, Inc.

NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD

Mustang Bio Inc (MBIO)

NASDAQ NMS - GLOBAL MARKET Biotechnology
Move probability → Options chain →
$0.38 -0.00 (-0.50%)
● At close: October 19 at 4:00:00 PM EDT
DAY'S RANGE $0.38
$0.38 $0.38
52-WEEK RANGE $0.38
$0.37 $1.57

What's happening

Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.

Key Statistics

Market Cap$2.9M
P/E (TTM1)—
EPS2 (TTM)$-0.46
Div Yield—
Beta32.19
Volume201
Open0.38
Prev Close0.38
Bid / Ask0.32 / 0.45
Next Earnings 2026-11-05

Analyst Recommendations

Strong buy 2 Buy 4 Hold 1 Sell 0 Strong sell 0

Aggregate ratings for 2024-12-01 (7 analysts polled by Finnhub) — consensus count.

Performance Overview (Trailing returns vs S&P 500 benchmark)

YTD RETURN
MBIO -60.97%
vs S&P 500 -74.34%
1-YEAR RETURN
MBIO -75.30%
vs S&P 500 -90.46%
6-MONTH RETURN
MBIO -50.28%
3-MONTH RETURN
MBIO -35.22%

Valuation Measures & Ratios

Enterprise Value4-$12.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book70.70
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-34.23%
Return on Assets (ROA9)-17.54%
Avg Volume (3M)34,950
Quarterly history (5 periods)
Measure Jun '26Mar '26Sep '25Jun '25Mar '25
Market cap $4.7M $5.0M $10.2M $8.1M $30.2M
P/E -1.43 -2.14 -3.65 -0.77 -2.02
Price/Book 0.62 0.58 1.04 2.80 8.38
ROE -43.17% -27.20% -28.58% -363.90% -414.33%
ROA -20.86% -14.10% -14.43% -80.67% -100.30%

Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).

Glossary — what these abbreviations mean
1. TTM
Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
2. EPS
Earnings per share — net income divided by diluted shares outstanding.
3. Beta
A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
4. EV (Enterprise Value)
Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
5. Forward P/E
Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
6. PEG Ratio
P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
7. Price / Book
Share price divided by book value (assets minus liabilities) per share.
8. ROE
Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
9. ROA
Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
10. MRQ
Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
11. YoY
Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.

Short Interest

Shares Short52,680
Change from Prior Settlement-9.96%
% of Float—
Days to Cover (Short Ratio)1.69

Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.

Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.

Price history

Events

Drag horizontally to zoom into a section; use Reset view to restore all observations.

Technical signal summary

Calculating from the latest year of daily price history…

Calculating…
Show Technical Analysis Breakdown ▾ 10 Indicators

Not investment advice — read several signals together.

Indicators None active

Add lines over the price chart or a panel below it. Your choices are saved on this device.

Starter sets
Trend
Oscillators
Volume/volatility
Loading chart…

History limited by data provider; markers are heuristics, not signals.

Peer and sector context

No reviewed peer group is available for this symbol.

Balanced evidence

A deterministic summary of sourced facts—not an AI verdict.

Potential strengths

  • Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗

Potential concerns

Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.

No accessible free API for these — links go to the source directly.

Morningstar Motley Fool MarketBeat

Financials

Income statement

Line item Jun '26Mar '26Sep '25Jun '25Mar '25Sep '24Jun '24Mar '24
Revenue — — — — — — — —
Operating income -$1.2M -$1.1M -$624.0K -$885.0K -$253.0K -$1.5M -$8.5M -$5.2M
Net income -$1.1M -$955.0K -$468.0K -$762.0K -$153.0K -$1.4M -$8.2M -$5.2M
EPS (diluted) $-0.16 $-0.14 $-0.07 $-0.19 $-0.05 $-1.96 $-18.36 $-24.81
EPS (basic) $-0.16 $-0.14 $-0.07 $-0.19 $-0.05 $-1.96 $-18.36 $-24.81

Balance sheet

Line item Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24
Total assets $15.6M $16.6M $17.6M $19.4M $13.0M $14.9M $9.3M $7.2M
Total liabilities $8.1M $8.0M $8.1M $9.6M $10.2M $11.3M $13.2M $15.8M
Stockholders' equity $7.5M $8.6M $9.5M $9.8M $2.9M $3.6M -$3.9M -$8.7M
Total current assets — — $17.6M $19.4M $13.0M $14.9M $8.6M $6.1M
Total current liabilities $7.9M $7.8M $7.9M $9.4M $10.0M $11.2M $12.6M $15.0M
Cash & equivalents $15.2M $16.3M $17.3M $19.0M $12.7M $14.2M $6.8M $3.5M

Cash flow

Line item Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24
Operating cash flow -$967.0K -$1.0M -$1.7M -$818.0K -$1.3M -$1.4M -$2.0M -$1.8M
Investing cash flow $0 $0 $0 $0 $0 $1.2M $0 $0
Financing cash flow -$141.0K $0 $0 $7.1M -$235.0K $7.6M $4.9M $1.0M
Free cash flow — — — — — — -$2.0M -$1.8M
Capital expenditures — — — — — — $0 $0
Share-based compensation $21.0K $22.0K $91.0K $23.0K $45.0K $38.0K -$526.0K $42.0K

Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.

Institutional holders

SEC Form 13F filers holding MBIO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.

Institutional ownership is not available for this symbol right now.

Insider activity

Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2022-03-18 to 2026-04-24

Recent transactions

  • Most recent: Litchman Manuel MD (President, CEO and Interim CFO) — Tax withholding of 19 shares on 2026-04-24.

Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.

Insider purchases & sales, last 6 months

Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0

Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.

Insider roster

NameTitleMost Recent TransactionDateShares
Litchman Manuel MDPresident, CEO and Interim CFOTax withholding2026-04-2419
Fortress Biotech, Inc.Reporting personGrant / award2026-01-02278,385
Herskowitz NeilDirectorOpen market sale2025-12-30247
Chill Adam J.DirectorOpen market sale2025-12-304
Jin DavidDirectorOpen market purchase2025-12-30247
ZELEFSKY MICHAEL JDirectorGrant / award2023-07-057,246
ROSENWALD LINDSAY A MDDirectorGrant / award2023-07-057,246
WEISS MICHAEL SDirectorGrant / award2023-07-057,246

Recent transactions

DateInsiderTitleTransactionSharesPrice
2026-04-24Litchman Manuel MDPresident, CEO and Interim CFOTax withholding 19$0.75
2026-01-02Fortress Biotech, Inc.Reporting personGrant / award 278,385$0.00
2025-12-30Herskowitz NeilDirectorOpen market sale 247$0.96
2025-12-30Chill Adam J.DirectorOpen market sale 4$0.95
2025-12-30Jin DavidDirectorOpen market purchase 247$0.96
2025-09-29Fortress Biotech, Inc.Reporting personGrant / award 59,334$0.00
2025-04-24Litchman Manuel MDPresident, CEO and Interim CFOTax withholding 27$1.24
2025-03-31Fortress Biotech, Inc.Reporting personGrant / award 67,806$0.00

Recent SEC filings

Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR submissions · updated 2026-10-22 07:51 UTC

FiledFormReport periodOfficial filing
2026-10-158-K2026-10-13 View on SEC.gov →
2026-08-0510-Q2026-06-30 View on SEC.gov →
2026-05-0510-Q2026-03-31 View on SEC.gov →
2026-04-2742026-04-24 View on SEC.gov →
2026-04-178-K2026-04-15 View on SEC.gov →
2026-03-1910-K2025-12-31 View on SEC.gov →
2026-01-0542026-01-02 View on SEC.gov →
2025-12-3042025-12-30 View on SEC.gov →
2025-12-3042025-12-30 View on SEC.gov →
2025-12-3042025-12-30 View on SEC.gov →
2025-12-238-K2025-12-17 View on SEC.gov →
2025-11-0710-Q2025-09-30 View on SEC.gov →

Headlines about MBIO (Mustang Bio, Inc.). Links open the publisher — we don’t host full articles.

SEC filings ↓

← Back to the full dashboard · My watchlist